Tag
This article examines the real-world safety and efficacy of the extravascular implantable cardioverter defibrillator (EV-ICD) over 1 year, demonstrating effective arrhythmia management and an acceptable safety profile in a large, global pat
In adults with repaired Tetralogy of Fallot undergoing pulmonary valve replacement, an electrophysiology-guided ablation strategy significantly reduces ventricular tachycardia inducibility and long-term arrhythmic risk compared to empiric a
The InEurHeart trial demonstrates that computed tomography-guided ventricular tachycardia ablation significantly reduces procedure duration while maintaining safety and efficacy compared to conventional methods in patients with ischemic car
Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.
The PAM-VT 2 study reveals that cardiac MRI (LGE-CMR) performed 3 to 6 months after ventricular tachycardia ablation can accurately predict long-term recurrence risks by analyzing scar stability and conducting channels.
The CORECA study reveals that preprocedural 3D anatomic and substrate reconstruction from CT or MRI effectively identifies ventricular tachycardia targets in complex congenital heart disease, achieving 87.5% concordance with electroanatomic
The first-in-human VCAS trial demonstrates that high-voltage focal pulsed field ablation (PFA) safely delivers transmural lesions in thick ventricular scar tissue, significantly reducing ventricular tachycardia burden by 98% in high-risk pa
A landmark study has developed and validated the first clinical risk prediction models for RYR2-mediated CPVT, identifying key factors like age at treatment and prior symptoms that determine life-threatening outcomes despite beta-blocker th
